Meta-analysis of low dose DA [61 trials], no affect on all cause mortality, adverse events, need for renal replacement tx. + stat sig increase in UO and CrCl. [Annal Int Med 4/5/05;142:510-24].
A meta-analysis of 17 randomized trials involving about 600 pts (looking at significant endpoints, e.g. death, development of ARF, or need for dialysis) found only statistically insignificant benefits from renal-dose Dopamine vs. placebo (e.g. mortality 4.7% vs. 5.6%, ARF 15.3% vs. 19.5%, dialysis 13.9% vs. 16.5%) (Crit. Care Med. 29:1526, 2001--JW)
A randomized trial in 328 critically ill pts with early renal dysfunction also showed no sig. benefit (Lancet 356:2139, 2000--JW)